BioWorld Asia

Sep. 29, 2010

Actelion Shares Fall on Clazosentan Phase III Miss

Shares in Actelion Pharmaceuticals Ltd. dropped by almost 8 percent Monday on news that clazosentan failed to reach the primary endpoint in a Phase III pivotal trial in patients who had undergone surgical clipping to treat a form of stroke called aneurysmal subarachnoid hemorrhage (aSAH). (BioWorld International) Read More

Okairos Raises $21M for Vaccine Pipeline

Study Forces a Rethink of Clostridium's Virulence Factors

Vaxonco Starts Phase I Trial of Malaria Vaccine EPI300

Estonian Biobank Nearly Done, Sequencing of 500 to Begin

Biognosys Completes Guide to 20,300 Human Proteins

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 26, 2026.

Brain-computer interfaces are here but long road ahead

BioWorld

The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...

Illustration of red and white blood cells in an artery

Case report links APOLD1 variant to vascular-type bleeding disorder

BioWorld Science

Vascular-type bleeding disorder (BDVAS) is a rare, autosomal dominant disorder mainly caused by impaired vascular integrity.

2026 marks critical turning point for BCI technology

BioWorld

Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...

Next wave of BCI firms builds on pioneers to tackle challenges

BioWorld

With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...